Clinical Trials
29 trialsStudy of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Memorial Sloan Kettering Cancer Center
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
University of Washington
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NePtune
Hoosier Cancer Research Network
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
STEEL
RTOG Foundation, Inc.
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
M.D. Anderson Cancer Center
INTREPId (INTermediate Risk Erection PreservatIon Trial)
Brigham and Women's Hospital
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
The COSMYC Trial (COmbined Suppression of MYC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
Dana-Farber Cancer Institute
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
M.D. Anderson Cancer Center
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Hoosier Cancer Research Network
FASTR-2
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
PBS
Juravinski Cancer Center
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Aragon Pharmaceuticals, Inc.
Cardiovascular Events in GnRH Agonist vs. Antagonist
Rabin Medical Center
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Radiation Therapy Oncology Group
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
Medical University of South Carolina
FASTR
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
University of Washington
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Hoosier Cancer Research Network
NEPTUNE
Queen Mary University of London
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
Alliance for Clinical Trials in Oncology
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
The Methodist Hospital Research Institute
Degarelix Neo-Adjuvant Radical Prostatectomy Trial
University Health Network, Toronto